Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Accounts Payables: 2009-2025

Historic Accounts Payables for Aytu Biopharma (AYTU) over the last 15 years, with Sep 2025 value amounting to $12.3 million.

  • Aytu Biopharma's Accounts Payables fell 8.67% to $12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.3 million, marking a year-over-year decrease of 8.67%. This contributed to the annual value of $10.6 million for FY2025, which is 2.78% up from last year.
  • According to the latest figures from Q3 2025, Aytu Biopharma's Accounts Payables is $12.3 million, which was up 16.42% from $10.6 million recorded in Q2 2025.
  • Aytu Biopharma's Accounts Payables' 5-year high stood at $19.3 million during Q2 2021, with a 5-year trough of $9.4 million in Q3 2021.
  • Its 3-year average for Accounts Payables is $12.2 million, with a median of $12.0 million in 2025.
  • Per our database at Business Quant, Aytu Biopharma's Accounts Payables spiked by 118.02% in 2021 and then tumbled by 42.94% in 2022.
  • Over the past 5 years, Aytu Biopharma's Accounts Payables (Quarterly) stood at $15.6 million in 2021, then slumped by 32.20% to $10.6 million in 2022, then dropped by 1.01% to $10.5 million in 2023, then grew by 11.71% to $11.7 million in 2024, then fell by 8.67% to $12.3 million in 2025.
  • Its Accounts Payables was $12.3 million in Q3 2025, compared to $10.6 million in Q2 2025 and $12.0 million in Q1 2025.